Olmita (Olmesartan Medoxomil, Amlodipine)

Olmesartan Medoxomil and Amlodipine, the active ingredients in Olmita, is a combination antihypertensive presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Olmita as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmita, a combination of an angiotensin II receptor blocker and a calcium‑channel blocker, is indicated for conditions related to elevated blood pressure.

- Hypertension: lowers systolic and diastolic blood pressure and reduces cardiovascular risk. - Essential hypertension: provides sustained blood pressure control when monotherapy is insufficient. - High‑risk cardiovascular patients: contributes to risk reduction when combined with lifestyle measures.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, especially after standing. - Flushing: transient warmth and redness. - Fatigue: general tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, or throat. - Severe hypotension: markedly low blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes. - Hyperkalemia: elevated potassium levels. - Renal impairment: worsening kidney function. - Allergic reactions: rash, itching, or severe skin reactions.

Olmita should be used under medical supervision with attention to individual health status. - Pregnancy: avoid use; ARBs are contraindicated in the second and third trimesters. - Renal impairment: monitor kidney function and adjust therapy as needed. - Hepatic disease: use cautiously; liver function may be affected. - Electrolyte balance: check potassium levels regularly. - Drug interactions: review concomitant medications for potential additive effects. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Olmita may interact with several medicines; careful review is required.

Major Interactions (Avoid): - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole): increase amlodipine exposure. - Dual renin‑angiotensin system blockers (e.g., ACE inhibitors, other ARBs): heightened risk of renal dysfunction.

Moderate Interactions (Monitor Closely):\n- Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce antihypertensive effect. - Lithium: possible increase in lithium levels. - Simvastatin: amlodipine can raise statin concentrations, increasing myopathy risk. - Diuretics: may enhance hypotensive effect, requiring dose adjustment.